

COMMONWEALTH OF AUSTRALIA

IN THE MATTER OF : Australian Patent  
Application 696764 (73941/94). In the name of:  
Human Genome Sciences Inc.

-and-

IN THE MATTER OF: Opposition thereto by  
Ludwig Institute for Cancer Research, under  
Section 59 of the Patents Act.

STATUTORY DECLARATION

I, Tom Rapoport of Harvard Medical School, of Harvard University, Boston, Massachusetts,  
United States of America, declare as follows:

1. I am currently a Professor of Cell Biology for the Howard Hughes Medical Institute in the Department of Cell Biology at the Harvard Medical School in Boston, Massachusetts. In 1995, I was appointed Professor of Cell Biology at Harvard Medical School. Prior to that appointment, I was Group Leader at the Max-Delbruck-Center for Molecular Medicine, Germany, from 1992-1994. From 1985-1992, I was the Group Leader at the Institute for Molecular Biology, Germany. From 1972-1985, I was a Research Assistant at the Zentralinstitut for Molekularbiologie der Akademie der Wissenschaften der DDR.
2. Since the early 1970s, my research has focused on protein processing and intracellular transport and the role of signal sequences in protein translocation across cell membranes, as evidenced by my curriculum vitae, which lists the publications that I have authored or co-authored. My research in the area of protein translocation has encompassed bacterial, yeast and mammalian systems. I am also broadly interested in examples of nonclassical secretion

pathways of mammalian proteins, including, fibroblast growth factor (FGF).  
Now shown to me and marked "TP-1" is a copy of my curriculum vitae.

3. I have been asked by the Patent Attorneys representing Human Genome Sciences ("HGS") to review Australian Patent Application Au-B-696764 (73941/94) in the name of HGS, entitled "Vascular Endothelial Growth Factor-2" ("the HGS patent specification"), which claims priority and has a virtually identical specification to U.S. application no. 08/207,550, filed March 8, 1994. I have also been asked to provide my comments and opinions as to what the patent specification would provide or teach to one of ordinary skill in the art of protein processing as of the earliest filing date of the HGS patent specification, March, 1994. For purposes of this analysis, I considered not only what I knew and appreciated at the relevant time, but what was expected to be known by graduate students and postdoctoral fellows who were in my laboratory at the relevant time. I have also been asked to comment on the state of the art of signal sequences and protein processing as of the earliest filing date of the HGS patent specification, March, 1994.
4. By the late 1970s, secreted proteins and the signal sequences required to route these proteins through the cell were well understood. For example, it was known that specific signals, often called signal sequences, were required to direct secreted proteins outside of the cell. These signal sequences were known to be located at the N-terminus of the secreted protein and removed either during or shortly after translocation of the protein across the endoplasmic reticulum and to the outside of the cell.
5. By 1994, it was known that, in mammals, signal sequences were typically located at the beginning of the secreted protein, often comprising 20 amino acids, and were characterized by a stretch of at least six or seven consecutive hydrophobic amino acids, the majority of which are leucine residues. Outside of the consecutive hydrophobic residues, there were other known requirements

for signal sequences, including the type of residues which provide the information to direct the cell to remove the signal sequence, i.e., the cleavage site. This cleavage site was known to contain small aliphatic residues, such as alanines at positions -1 and -3 to the N-terminus of the cleavage site, and was known to be usually found five to seven residues downstream from the stretch of consecutive hydrophobic residues.

6. By 1994, researchers were able to characterize signal sequences by their hydrophobic nature. Such sequences were often identified by an inspection of the amino acid sequence. Alternatively, computer programs, such as P SORT and SIGNAL P were, and still are today, standard tools used to predict the presence or absence of signal sequences. There was however no certainty with such approaches.
7. I have reviewed and analyzed the polynucleotide, and amino acid sequence, identified by HGS to encode the human VEGF-2 protein, as set forth in Figure 1 of the HGS patent specification. The human VEGF-2 protein is described in the HGS patent specification as structurally related to the PDGF/VEGF family of growth factors, a known family of secreted proteins. The HGS patent specification further states that the VEGF-2 polynucleotide is predicted to contain an open reading frame of approximately 350 residues, which encodes VEGF-2. (See, the HGS patent specification at page 5, lines 25-27). The specification reports that at the amino acid level VEGF-2 exhibits the highest homology to vascular endothelial growth factor (30% identity), followed by PDGF alpha (23%) and PDGF beta (22%). (See, the HGS patent specification at page 5, lines 28-31). The VEGF-2 protein was further characterized in the HGS patent specification as containing eight cysteines which are conserved among all four members of the family, and in addition also contains the conserved or signature motif PXCXXXRCXGCCN which is found in all members of the PDGF/VEGF family. (See, the HGS patent specification at page 5, lines 31-33). The HGS patent specification speculates that the first 24

residues of the 350 amino acid sequence may encode a signal sequence. (See, the HGS patent specification at page 5, lines 26-27).

8. Attached as "Annexure TP-2" is an annotated copy of Figure 1 of the HGS patent specification which sets forth the nucleotide and amino acid sequence of VEGF-2 identified by HGS. The figure is further annotated to indicate specific amino acid residues and those portions of the VEGF-2 sequence which will become relevant throughout this declaration. For consistency of nomenclature, the numbering of amino acid residues will be referred to in the context of what is now known as the 419 amino acid form of VEGF-2. As shown in Annexure TP-2, the 350 amino acid form of VEGF-2 corresponds to amino acid residues 70 to 419 of the 419 form of VEGF-2.
9. By 1994, had I or any one skilled in the art, such as any Ph.D. scientist or candidate in my laboratory, been presented with the HGS patent specification, (see ¶ 7 above) one would recognize that the VEGF-2 protein is a secreted protein. Based on the characterization of the VEGF-2 protein set forth in the HGS patent specification, one would recognize that the protein was a member of the PDGF/VEGF family of growth factors. The PDGF/VEGF family of growth factors, like other growth factors, must be secreted in order to exert their growth promoting or mitogenic effects. Since all previously identified members of the PDGF/VEGF family were known to be secreted, one would expect the newly identified VEGF-2 to also be secreted.
10. Had I or any skilled artisan been presented with the HGS patent specification in 1994 and wanted to express the VEGF-2 protein, one would proceed with inspecting the 350 amino acid sequence set forth in Figure 1 to identify a potential signal sequence. As I have already noted, by 1994, this was routinely achieved by visual inspection or could be achieved with the aid of a computer program. Upon inspection of the N-terminal portion of the 350 amino acid sequence, I did not observe the typical conserved motif of a signal sequence.

In fact, the N-terminal portion of the 350 amino acid sequence is not very hydrophobic and contains many charged residues. However, provided with the strong evidence that the 350 amino acid sequence was a secreted protein based on the teaching and recognition of the HGS patent specification that it is a member of a family of secreted growth factors (see ¶ 7 above), I would not rule out that the 350 amino acid sequence may contain an atypical signal sequence. Atypical signal sequences are not without precedent. For example, as of March 1994, it was known that ovalbumin, a secreted protein, contains an atypical and uncleaved signal sequence that is not immediately obvious on simple inspection.

11. The possibility of additional upstream coding regions from the sequence disclosed in Figure 1 of the HGS patent specification would not have dissuaded me nor do I believe it would have dissuaded my Ph.D. students or post-doctorate students from attempting to express the 350 amino acid sequence. By 1994, it was well established that the PDGF/VEGF family of growth factors were expressed initially as precursor proteins which underwent proteolytic processing resulting in a mature form of the protein. Thus, I would predict VEGF-2 to be expressed in a similar way. The 350 amino acid sequence set forth in Figure 1 contains those conserved motifs which are signature motifs for an active form of the protein belonging to the PDGF/VEGF family. Thus in 1994, I would have predicted the protein encoded by the sequence disclosed in Figure 1, containing motifs characteristic of the PDGF/VEGF family, to be secreted and biologically active.
12. By 1994, in order to ensure secretion of the VEGF-2 sequence disclosed in Figure 1, I would have engineered a heterologous signal sequence upstream from the methionine at position 70. Indeed, this approach is specifically taught in the HGS patent specification (at page 14, lines 6-23). Moreover, it would have involved routine practice in 1994 to select a strong signal sequence, such as that of human growth factor or insulin growth factor, and to

engineer such a construct to achieve expression and secretion of the gene product. Even given the possibility that the 350 amino acid sequence may contain an atypical signal sequence, I would still have utilized a strong signal sequence to ensure efficient secretion of the protein, and it would have been standard practice to do so. The upstream signal sequence would be expected to override any weaker signal sequence that may be present downstream, and none of the segments of amino acids in the 350 amino acid sequence are hydrophobic enough to prevent the secretion of the protein through the endoplasmic reticulum and to the outside of the cell. Thus, I would have fully expected to achieve expression and secretion of the VEGF-2 protein using a heterologous signal sequence.

13. The expectation that engineering a signal sequence upstream of the sequence set forth in Figure 1 would result in the expression and secretion of a biologically active protein as set forth in the HGS patent specification, has in fact been subsequently confirmed by one skilled in the field of VEGF-2, Dr. Kari Alitalo. Drs. Kari Alitalo and Vladimir Joukov are named as co-inventors of U.S. Patent No. 6,130,071, issued October 10, 2000, entitled: "Vascular Endothelial Growth Factor C (VEGF-C) Cys 156 Protein and Uses Thereof" (the "Alitalo Patent"). It is my understanding that VEGF-2 and VEGF-C are terms used to refer to the same molecule. The Alitalo Patent describes several fragments of VEGF-C which were engineered to be expressed and secreted from cells. Cells were engineered to express the VEGF-2 fragments by fusing a signal sequence to the nucleotide sequence encoding the protein fragment. Secreted protein fragments were obtained from the cell culture medium and tested for activity. The working examples of the Alitalo Patent demonstrate that VEGF-C fragments spanning residues 103-419 or 112-419 (see Annexure TP-2) which are fused in frame to a signal sequence are secreted into the culture medium. (Alitalo Patent, column 47, lines 44 to 48). The Alitalo Patent also demonstrates the use of a heterologous signal sequence to ensure secretion of a fragment of VEGF-C. A fragment

spanning residues 104-213 (see Annexure TP-2) was fused in frame to a heterologous signal sequence which resulted in the secretion of a biologically active form of VEGF-C. (Alitalo Patent, column 46, lines 5 to 10).

Furthermore, a publication subsequent to the priority date of the HGS patent specification, which Dr. Alitalo co-authored, Joukov et al, 1997, EMBO J. 16:3898-3911 ("Joukov"), describes two VEGF-C mutants in which the native VEGF-C signal sequence was fused in frame with residues 103-419 or residues 103-227. Both VEGF-C mutants were shown to be secreted into the culture medium, (Joukov at page 3901) using experimental procedures that were routine by 1994. Thus, both Alitalo and Joukov confirm that the fusion of a signal sequence in frame to VEGF-2 fragments will result in secreted protein fragments.

14. The expectation that I would have had from reading the HGS patent specification and the expectation that I would have expected others to have had is that the sequence set forth in Figure 1 does indeed contain the conserved motifs which would confer biological activity to the VEGF-2 protein as set forth in the HGS patent specification (see ¶ 7 above) has also been subsequently confirmed by Dr. Alitalo. In the Alitalo Patent and Joukov, the VEGF-2 protein fragments were tested for VEGF-C biological activity in different assays. The Alitalo Patent expressed and assayed several fragments in this manner, including fragments spanning residues 103-225, 103-419, 104-213, and 112-419 (see Annexure TP-2), and as described in ¶ 13, above. Each of the fragments assayed were found to be biologically active. Based on these observations and sequence comparisons of the VEGF family, the Alitalo Patent states that still smaller fragments of the 419 amino acid sequence of VEGF-C will retain biological activity. (Alitalo Patent, column 47, line 57 to column 48, line 2). The Alitalo Patent further states that a protein which retains the conserved motif RCXXCC (e.g., a polypeptide comprising from about residue 161 to about residue 211, see Annexure TP-2) is postulated to

retain biological activity. (Alitalo Patent, column 47, line 57 to column 48, line 2).

15. As observed in the Alitalo Patent and Joukov, VEGF-C fragments spanning residues 103-225, 103-419, 104-213, and 112-419 (see Annexure TP-2) fused in frame with signal sequences contained sufficient information to be processed by the cell to result in a biologically active form of VEGF-C. Furthermore, Alitalo also predicts that a VEGF-C fragment spanning residues 161-211 of VEGF-C (see Annexure TP-2) contains sufficient information to confer biological activity. Thus, if these VEGF-C fragments spanning residues 103-225, 103-419, 104-213, 112-419 and 161-211 contain sufficient information to allow for processing of a biologically active form of VEGF-C, the longer sequence set forth in the HGS patent specification which spans residues 70-419 (see Annexure TP-2), fused in frame to a signal sequence, should also contain sufficient information to be processed by the cell to result in a biologically active form of VEGF-C. According to the Alitalo Patent and Joukov, proteolytic processing of VEGF-C appears to differ depending on the cell used to achieve expression of the VEGF-C protein (Joukov at ¶ spanning pages 3906-3907). However, both Alitalo and Joukov demonstrate that regardless what type of mammalian or yeast cells are used to express VEGF-C, a biologically active VEGF-C protein is obtained. (Joukov at ¶ spanning pages 3906-3907; Alitalo Patent at column 46, lines 5-10). Consequently, regardless of the cell line used to express VEGF-C and the exact proteolytic processing or glycosylation that results, a biologically active fragment of VEGF-C can still be obtained. Thus, consistent with the teaching of the HGS patent specification, residues 70-419 as set forth in Figure 1 also contain sufficient information to confer VEGF-C biological activity.
16. The Alitalo Patent and Joukov have clearly confirmed that the teaching of the HGS patent specification, that the fusion of a signal sequence to a fragment of VEGF-C will result in the successful secretion of that fragment from the cell



into the culture medium. Thus, according to the teaching of the HGS patent specification, residues 70-419 as set forth in Figure 1 fused in frame to a signal sequence will result in its successful secretion from the cell into the culture medium.

17. In sum, as described in the HGS patent specification, Dr. Alitalo has subsequently demonstrated and/or predicted that VEGF-C fragments spanning residues 103-227, 103-419, 104-213, 112-419 and 161-211 (see Annexure TP-2) when fused in frame to a signal sequence result in a secreted gene product which retains VEGF-C biological activity. Thus, the sequence set forth in the HGS patent specification, spanning residues 70 to 419 of VEGF-C (see Annexure TP-2) fused in frame to a signal sequence should also result in a protein which is secreted and retains VEGF-C biological activity.
18. In my opinion, I or one skilled in the art would identify the VEGF-2 protein as a novel member of the PDGF/VEGF family of growth factors, and as such, would recognize that VEGF-2 is also a secreted growth factor, based on the HGS patent specification in combination with the state of the art as of March, 1994. I or one skilled in the art would recognize the utility in using a heterologous signal sequence to achieve expression and secretion of the VEGF-2 protein, based on the HGS patent specification in combination with the state of the art as of March, 1994. Hence, I or one skilled in the art following the teaching of the HGS patent specification coupled with the knowledge of the art at March 1994, would have predicted and expected to achieve expression and secretion of a protein which retains VEGF-2 biological activity and it would have been obvious to carry out those experiments to achieve that purpose.

AND I declare further that all statements made in this Declaration of my own are true in every particular, and that all statements made on information and belief are believed to be true.

Sworn by the said Tom Rapoport, [Signature]  
at Boston Massachusetts, on this 13<sup>th</sup> day of <sup>December</sup> ~~November~~ 2000;

before me: [Signature]

Notary Public

LORNA L. FARGO

MY COMM. EXPIRES 12-01-06

Curriculum vitae

Name: Tom A. Rapoport

Address: Howard Hughes Medical Institute  
Harvard Medical School  
Department of Cell Biology  
240 Longwood Avenue  
Boston, MA 02115-6091

private address:

65 Greenough Street  
Brookline, MA 02445

Phone: (617) 432-0637 (office)  
(617) 566-6575 (home)

Personal data: born 06/17/47 in Cincinnati (USA)  
married, 3 children

Education: 1965 - 1966 High school specialized in mathematics  
and natural sciences at the Humboldt-  
University Berlin, graduation with  
"honors"

1966 - 1972 Study of chemistry and biochemistry  
at the Humboldt-University Berlin,  
graduation with "honors"

1972 Ph.D. for work on "The mechanism of  
the inorganic pyrophosphatase of  
baker's yeast"

1977 "Habilitation" for work on "The  
development of a control theory for  
the mathematical modelling of  
metabolic pathways"

Areas of research: 1969 - 1972 enzyme kinetics, enzymology, protein  
purifications

	1970 - 1980	mathematical modelling of metabolic systems, studies on the regulation of the glycolysis in erythrocytes
	1972 - 1980	biosynthesis of carp insulin, cloning of the cDNA for carp insulin, expression of the gene in E.coli, oocyte injection of mRNAs
	1972 -	intracellular protein transport, transport of proteins across the endoplasmic reticulum membrane, membrane biogenesis
Academic positions:	1972 - 1985	Research Assistant at the Zentralinstitut für Molekularbiologie der Akademie der Wissenschaften der DDR
	1985 - 1992	Professor of Cell Biology
	1985 - 1992	Group Leader at the Institute for Molecular Biology
	1992 - 1994	Group Leader at the Max-Delbrück-Center for Molecular Medicine
	1995 - 1997	Professor of Cell Biology at Harvard Medical School
	1997 - present	HHMI Professor of Cell Biology at Harvard Medical School
Memberships:	German Biochemical Society Academy of Sciences Academia Europea EMBO American Society for Cell Biology	
Honors:	Johannes-Müller-prize of the Society for Experimental Medicine  Rudolf-Virchow-prize	

Sabbatical: 1982 3 month stay in the laboratory of Dr. G. Blobel (Rockefeller University New York)

Major Committee Assignments:

1996-1997	Standing Committee on Promotions, Reappointments and Appointments in the Faculty of Medicine at Harvard Medical School
1996-present	Various promotion committees
1996-present	Various Ph.D. Thesis Committees
1997-1999	Vice Chair/Chair, Gordon Research Conference on Molecular Membrane Biology
1999-present	NIH study section (permanent member)

Editorial Boards:

1980-1988	FEBS Letters
1989-present	EMBO Journal
1989-present	The Journal of Cell Biology
2000	EMBO Reports

Teaching Report:

1996-1998	Co-director, Cell Biology 201 course
1999-2000	Director, Cell Biology 201 course
1998-1999	CBC course (medical students)
1998-1999	Molecular Machines course

# List of publications

01. Rapoport, T. A., Höhne, W. E., Reich, J. G., Heitmann, P., and Rapoport, S. M. (1972) Eur. J. Biochem. 26, 237-246  
A kinetic model for the action of the inorganic pyrophosphatase from baker's yeast; the activating influence of magnesium ions
02. Höhne, W. E., Rapoport, T. A., and Heitmann, P. (1972) Acta biol. med. germ. 29, 841-850  
Eine automatische Apparatur zur Ermittlung der kinetischen Parameter enzymatischer Reaktionen
03. Höhne, W. E. and Rapoport, T. A. (1973) Eur. J. Biochem. 33, 323-331  
Slow conformational changes of the inorganic pyrophosphatase from baker's yeast induced by divalent metal ions
04. Rapoport, T. A., Höhne, W. E., Heitmann, P., and Rapoport, S. M. (1973) Eur. J. Biochem. 33, 341-347  
Binding of ligands to the inorganic pyrophosphatase of baker's yeast
05. Heinrich, R. and Rapoport, T. A. (1973) Abhandlg. d. AdW der DDR VII. Internat. Symp. über Struktur und Funktion der Erythrozyten, S. 21-27  
On the theory of enzymatic systems with application to the glycolysis of erythrocytes
06. Heinrich, R. and Rapoport, T. A. (1973) Acta biol. med. germ. 31, 479-494  
Linear theory of enzymatic chains; its application for the analysis of the crossover theorem and of the glycolysis of human erythrocytes
07. Heinrich, R. and Rapoport, T. A. (1974) Eur. J. Biochem. 42, 89-95  
A linear steady state treatment of enzymatic chains; general properties, control and effector strength
08. Heinrich, R. and Rapoport, T. A. (1974) Eur. J. Biochem. 42, 97-105  
A linear steady state treatment of enzymatic chains; critique of the crossover theorem and a general procedure to identify interaction sites with an effector
09. Rapoport, T. A., Heinrich, R., Jacobasch, G., and Rapoport, S. M. (1974) Eur. J. Biochem. 107-120  
A linear steady state treatment of enzymatic chains; a mathematical model of the glycolysis of human erythrocytes
10. Lukowsky, A., Prehn, S., and Rapoport, T. A. (1974) Biochem. Biophys. Acta 359, 248-252

Biosynthesis of proinsulin in islets of Langerhans of carp (*Cyprinus carpio*)

11. Rapoport, T. A., Prehn, S., Lukowsky, and A., Junghahn, I. (1974) *Acta Biol. med. germ.* 33, 953-961

Biosynthesis of proinsulin of carp (*Cyprinus carpio*)

12. Heinrich, R. and Rapoport, T. A. (1974) *Symp. Biol. Hung.* 18, 173-212

The regulatory principles of the glycolysis of erythrocytes in vivo and in vitro

13. Rapoport, S. M., Rapoport, T. A., and Heinrich, R. (1974) 9th FEBS meeting Budapest, Publ. House Hung. Acad. Sci. p. 195-209

The regulation of glycolysis in erythrocytes

14. Rapoport, T. A. and Heinrich, R. (1975) *Bio Systems* 7, 120-129

Mathematical analysis of multienzyme systems; I. Modelling of the glycolysis of human erythrocytes

15. Heinrich, R. and Rapoport, T. A. (1975) *Bio Systems* 7, 130-136

Mathematical analysis of multienzyme system control

16. Rapoport, T. A., Heinrich, R. and Rapoport, S. M. (1976) *Biochem. J.* 154, 449-469

The regulatory principles of glycolysis in erythrocytes in vivo and in vitro; a minimal comprehensive model describing steady states and time-dependent processes

17. Rapoport, T. A., Höhne, W. E., Klatt, D., Prehn, S., and Hahn, V. (1976) *FEBS Letters* 69, 32-36

Evidence for the synthesis of a precursor of carp proinsulin in a cell free translation system

18. Rapoport, T. A. and Heinrich, R. (1977) *Mathematische Modellbildung*, Akademie/Verl., Berlin, S. 208-219

Modellierung metabolischer Systeme

19. Rapoport, T. A., Otto, M., and Heinrich, R. (1977) *Acta biol. med. germ.* 36, 461-468

An extended model of the glycolysis in erythrocytes

20. Schulz, J., Baufeld, A., Hofmann, E., Rapoport, T. A., Heinrich, R., and Rapoport, S. M. (1977) *Acta biol. med. germ.* 36, 1379-1391

Regulation of anaerobic glycolysis in Ehrlich ascites tumour cells

21. Heinrich, R., Rapoport, S. M., and Rapoport, T. A. (1977) *Prog. Biophys. Molec. Biol.* 32, 1-82  
Metabolic regulation and mathematical models
22. Rapoport, I., Rapoport, T. A., and Rapoport, S. M. (1978) *Acta biol. med. germ.* 37, 393-401  
Analysis of pH-induced changes of the glycolysis of human erythrocytes
23. Rapoport, T. A., Kohnert, K.-D., Knospe, S., Lukowsky, A., Prehn, S., Schäfer, H., Schmidt, S., and Ziegler M. (1978) *Acta biol. med. germ.* 37, 1153-1160  
Preparation and characterization of insulin of carp (*Cyprinus carpio*)
24. Rapoport, T. A., Thiele, B., Prehn, S., Marbaix, G., Cleuter, Y., Hubert, E., and Huez, G. (1978) *Eur. J. Biochem.* 87, 229-233  
Synthesis of Carp proinsulin in *Xenopus* oocytes
25. Grosse, R., Rapoport, T. A., Malur, J., Fischer, J., and Repke, K. R. H. (1979) *Biochim. Biophys. Acta* 550, 500-514  
Mathematical modelling of ATP, K<sup>+</sup> and Na<sup>+</sup> interactions with the Na<sup>+</sup> - K<sup>+</sup> -ATPase occurring under equilibrium conditions
26. Rosenthal, S., Coutelle, Ch., Hahn, V., Liebscher, D. H., and Rapoport, T. A. (1979) *Studia biophysica* 76, 147-148  
Cloning of vertebrate genes in *E. coli*: perspective for basic research. technical microbiology and medicine/considering own data
27. Rapoport, T. A., Prehn, S., Huth, A., and Tsamaloukas, A. (1980) *Physiol. Sci.* 13, 135-146  
Biosynthesis of proinsulin of carp
28. Rapoport, T. A., Prehn, S., and Tsamaloukas, A. (1980) (Augustyniak, J., ed), Elsevier, North-Holland, pp 215-228  
Biological implications of protein-nucleic acid interactions
29. Prehn, S., Tsamaloukas, A., and Rapoport, T. A. (1980) *Eur. J. Biochem.* 107, 185-195  
Demonstration of specific receptors of the rough endoplasmic reticulum membrane for the signal sequence of carp preproinsulin
30. Liebscher, D. H., Coutelle, Ch., Rapoport, T. A., Hahn, V., Rosenthal, S., Prehn, S., and Williamson, R. (1980) *Gene* 9, 233-246  
Cloning of carp preproinsulin cDNA in the bacterial plasmid



31. Rapoport, T. A., Prehn, S., Tsamaloukas, A., Coutelle, Ch., Liebscher, D. H., Huth, A., and Rosenthal, S. (1980) *Ann. N. Y. Acad. Sci.* 343, 111-132  
Biosynthesis of proinsulin of carp (*cyprinus carpio*) and characterization and cloning of mRNA
32. Heinrich, R. and Rapoport, T. A. (1980) *J. Theoret. Biol.* 86, 279-313  
Mathematical modelling of translation of mRNA in eucaryotes; steady states, time-dependent processes and application to reticulocytes
33. Rapoport, T. A. (1981) *Eur. J. Biochem.* 115, 665-669  
Intracellular compartmentation and secretion of carp proinsulin synthesized in *Xenopus* oocytes
34. Prehn, S., Nürnberg, P., and Rapoport, T. A. (1981) *FEBS Letters* 123, 79-84  
A receptor for signal segments of secretory proteins in rough endoplasmic reticulum membranes
35. Huth, A. and Rapoport, T. A. (1982) *Gen. Comp. Endocrinol.* 46, 158-167  
Regulation of the biosynthesis of insulin in isolated Brockmann bodies of the carp (*cyprinus carpio*)
36. Makower, A., Dettmer, R., Rapoport, T. A., Knospe, S., Behlke, J., Prehn, S., Franke, P., Etzold, G., and Rosenthal, S. (1982) *Eur. J. Biochem.* 122, 339-345  
Carp insulin: amino acid sequence, biological activity and structural properties
37. Bendzko, P., Prehn, S., Pfell, W., and Rapoport, T. A. (1982) *Eur. J. Biochem.* 123, 121-126  
Different modes of membrane interactions of the signal sequence of carp preproinsulin and of the insertion sequence of rabbit cytochrome b5
38. Bassüner, R., Huth, A., Manteuffel, R., and Rapoport, T. A. (1983) *Eur. J. Biochem.* 133, 321-326  
Secretion of plant storage globulin polypeptides by *Xenopus laevis* oocytes
39. Finkelstein, A. V., Bendzko, P., and Rapoport, T. A. (1983) *FEBS Letters* 161, 176-179  
Recognition of signal sequences
40. Hahn, V., Winkler, J., Rapoport, T. A., Liebscher, D. H., Coutelle, Ch., and Rosenthal, S. (1983) *Nucl. Acid Res.* 11, 4541-4552  
Carp preproinsulin cDNA sequence and evolution of insulin genes

41. Rapoport, T. A., Huth, A., Prösch, S., Bendzko, P., Kääriäinen, L., Bassüner, R., Manteuffel, R., and Finkelstein, A. (1983) in: Protein synthesis (Abraham, A. K. K., Eikhom, T. S., and Pryme, I. F., eds) The Humana Press, Clifton, New Jersey, pp 81-100  
  
Transport of proteins and signal recognition
42. Bassüner, R., Wobus, U., and Rapoport, T. A. (1984) FEBS Letters 166, 314-320  
  
Signal recognition particle triggers the translocation of storage globulin polypeptides from field beans (*Vicia faba* L.) across mammalian endoplasmic reticulum membrane
43. Huth, A., Rapoport, T. A., and Kääriäinen, L. (1984) EMBO-J. 3, 767-771  
  
Envelope proteins of Semliki Forest virus synthesized in *Xenopus* oocytes are transported to the cell surface
44. Wiedmann, M., Huth, A., and Rapoport, T. A. (1984) Nature (Lond.) 309, 637-639  
  
*Xenopus* oocytes can secrete bacterial  $\beta$ -lactamase
45. Pfeiffer, M., Hahn, V., Huth, A., Liebscher, D. H., Pöhlmann, Ch., Rapoport, T.A., Rosenthal, S., Tran-Batcke, A., and Wolf, M. (1984) Biol. Zbl. 103, 637-647  
  
Expression of the DNA sequence coding for carp preproinsulin in *E. coli*-initiation of translation at the eukaryotic start codon
46. Rapoport, T. A. and Wiedmann, M. (1985) Curr. Topics in Membranes and Transport 24, 1-62  
  
Application of the signal hypothesis to the incorporation of integral membrane proteins
47. Rapoport, T. A. (1985) FEBS Letters 187, 1-10  
  
Extensions of the signal hypothesis-sequential insertion model versus amphipathic tunnel hypothesis
48. Rapoport, T. A. (1986) CRC Crit. Rev. Biochem. 20, 73-137  
  
Protein translocation across, and integration into, membranes
49. Kurzchalia, T. V., Wiedmann, M., Girshovich, A. S., Bochkareva, E. S., Bielka, H., and Rapoport, T. A. (1986) Nature 320, 634-636.  
  
The signal sequence of nascent preprolactin interacts with the 54K polypeptide of the signal recognition particle
50. Wiedmann, M., Huth, A., and Rapoport, T. A. (1986) FEBS Letters 194, 139-145  
  
Internally transposed signal sequence of carp preproinsulin retains its function with the signal recognition particle

51. Wiedmann, M., Huth, A., and Rapoport, T. A. (1986) *Biochem. Biophys. Res. Commun.* 134, 790-796
- A signal sequence is required for the functions of the signal recognition particle
52. Wiedmann, M., Kurzchalia, T. V., Bielka, H., and Rapoport, T. A. (1987) *J. Cell Biol.* 104, 201-208.
- Direct probing of the interaction between the signal sequence of nascent preprolactin and the signal recognition particle by specific crosslinking
53. Rapoport, T. A., Heinrich, R., Walter, P., and Schulmeister, Th. (1987) *J. Mol. Biol.* 195, 621-636.
- Mathematical modelling of the effects of the signal recognition particle on translation and translocation of proteins across the endoplasmic reticulum membrane
54. Prehn, S., Wiedmann, M., Rapoport, T. A., and Zwieb, Ch. (1987) *EMBO-J.* 6, 2093-2097
- Protein translocation across wheat germ microsomal membranes requires an SRP-like component
55. Wiedmann, M., Kurzchalia, T. V., Hartmann, E., and Rapoport, T. A. (1987) *Nature* 328, 830-833
- A signal sequence receptor in the endoplasmic reticulum membrane
56. Kurzchalia, T. V., Wiedmann, M., Breter, H., Zimmermann, W., Bauschke, E., and Rapoport, T. A. (1988) *Eur. J. Biochem.* 172, 663-668
- tRNA-mediated labelling of proteins with biotin: a non-radioactive method for the detection of cell-free translation products
57. Bassüner, R., Bäumlein, H., Huth, A., Jung, R., Wobus, U., Rapoport, T. A., Saalbach, G., and Müntz, K. (1988) *Plant. Mol. Biol.* II, 321-334
- Abundant embryonic mRNA in field bean (*Vicia faba* L.) codes for a new class of seed proteins: cDNA cloning and characterization of the primary translation product
58. Wiedmann, M., Wiedmann, B., Voigt, S., Wachter, E., Müller, H.-G., and Rapoport, T. A. (1988) *EMBO-J.* 7, 1763-1768
- Post-translational transport of proteins into microsomal membranes of *Candida maltosa*
59. Hartmann, E., Wiedmann, M., and Rapoport, T. A. (1989) *EMBO-J.* 8, 2225-2229
- A membrane component of the endoplasmic reticulum that may be essential for protein translocation

60. Huth, A., Petrukhin, K. E., Modyanov, N. N., and Rapoport, T. A. (1989) Biomed. Biochim. Acta 48, 77-84
- SRP-dependent membrane integration of the beta-subunit of Na<sup>+</sup>, K<sup>+</sup>-ATPase
61. Wiedmann, M., Görlich, P., Hartmann, E., Kurzchalia, T. V., and Rapoport, T. A. (1989) FEBS Lett. 257, 263-268
- Photocrosslinking demonstrates proximity of the 34kDa-membrane protein to different portions of preprolactin during translocation through the endoplasmic reticulum
62. Rapoport, T. A., Wiedmann, M., Kurzchalia, T. V., and Hartmann, E. (1989) Biochem. Trans. 17, 325-328
- Signal recognition in protein translocation across the endoplasmic reticulum membrane
63. Bernstein, H. D., Rapoport, T. A., and Walter, P. (1989) Cell 58, 1017-1019
- Cytosolic protein translocation factors: Is SRP still unique?
64. Hartmann, E., Rapoport, T. A., and Lodish, H. F. (1989) Proc. Natl. Acad. Sci. USA 86, 5786-5790
- Predicting the orientation of eukaryotic membrane-spanning proteins
65. Prehn, S., Herz, J., Hartmann, E., Kurzchalia, T. V., Frank, R., Römisch, K., Dobberstein, B., and Rapoport, T. A. (1990) Eur. J. Biochem. 188, 439-445
- Structure and biosynthesis of the signal sequence receptor
66. Müsch, A., Hartmann, E., Rohde, K., Rubartelli, A., Sitia, R., and Rapoport, T. A. (1990) Trend Biochem. Sci. 15, 86-88
- A novel pathway for secretory proteins?
67. Rapoport, T. A. (1990) Trends Biochem. Sci. 15, 355-358
- Protein transport across the ER membrane
68. Görlich, D., Prehn, S., Hartmann, E., Herz, J., Otto, A., Kraft, R., Wiedmann, M., Knespel, S., Dobberstein, B., and Rapoport, T. A. (1990) J. Cell Biol. 111, 2283-2294
- The signal sequence receptor has a second subunit and is part of a translocation complex in the endoplasmic reticulum as probed by bifunctional reagents
69. Vogel, F., Hartmann, E., Görlich, D., and Rapoport, T. A. (1990) Eur. J. Cell Biol. 53, 197-202

Segregation of the signal sequence receptor protein in the rough endoplasmic reticulum membrane

70. Rapoport, T. A. (1991) *Nature* 349, 107-108  
A bacterium catches up
71. Rapoport, T. A. (1991) *FASEB-Journal* 5, 2792-2798  
Protein transport across the endoplasmic reticulum membrane: facts, models, mysteries
72. Görlich, D., Kurzchalia, T. V., Wiedmann, M., and Rapoport, T. A. (1991) *Meth. Cell Biol.* 34, 241-261  
Probing the molecular environment of translocating polypeptide chains by crosslinking
73. High, S., Görlich, D., Wiedmann, M., Rapoport, T. A., and Dobberstein, B. (1991) *J. Cell Biol.* 113, 35-44  
The identification of proteins in the proximity of signal-anchor sequences during their targeting to and insertion into the membrane of the ER
74. Rapoport, T. A., Görlich, D., Müsch, A., Hartmann, E., Prehn, S., Wiedmann, M., Otto, A., Kostka, S., and Kraft, R. (1991) *Antonie van Leeuwenhoek* 61, 119-122  
Components and mechanism of protein translocation across the ER membrane
75. Müsch, A., Wiedmann, M., and Rapoport, T. A. (1992) *Cell*, Vol. 69, 343-352  
Yeast Sec-proteins interact with polypeptides traversing the endoplasmic reticulum membrane
76. Görlich, D., Hartmann, E., Prehn, S., and Rapoport, T. A. (1992) *Nature*, Vol. 357, 47-52  
A protein of the endoplasmic reticulum involved early in polypeptide translocation
77. Hartmann, E., Rapoport, T. A., and Prehn, S. (1992) *Nature* 358, 198.  
Signal sequence identified
78. Görlich, D., Prehn, S., Hartmann, E., Kalies, K.-U., and Rapoport, T.A. (1992) *Cell* 71, 489-503  
A mammalian homolog of Sec61p and SecYp is associated with ribosomes and nascent polypeptides during translocation
79. Rapoport, T. A. (1992) *Science* 258, 931-936  
Transport of proteins across the endoplasmic reticulum (ER) membrane

80. Hartmann, E. and Rapoport, T.A. (1992) in: Membrane Biogenesis and Protein Targeting (Neupert, W. and Lill, R., Eds.; Elsevier) 119-127  
 Translocation of proteins through the endoplasmic reticulum membrane: investigation of their molecular environment by cross-linking
81. Kutay, U., Hartmann, E. and Rapoport, T.A. (1993) Trends in Cell Biology 3, 72-75  
 A class of membrane proteins with a C-terminal anchor
82. Hartmann, E., Görlich, D., Kostka, S., Otto, A., Kraft, R., Knespel, S., Bürger, E., Rapoport, T.A. and Prehn, S. (1993) Eur. J. Biochem. 214, 375-381  
 A tetrameric complex of membrane proteins in the endoplasmic reticulum
83. High, St., Andersen, S.S.L., Görlich, D., Hartmann, E., Prehn, S., Rapoport, T.A. and Dobberstein, B. (1993) The Journal of Cell Biology 121, 4, 743-750  
 Sec61p is Adjacent to Nascent Type I and Type II Signal-Anchor Proteins during Their Membrane Insertion
84. Görlich, D. and Rapoport, T.A. (1993) Cell 75, 615-630  
 Protein Translocation into Proteoliposomes Reconstituted from Purified Components of the ER membrane
85. Jungnickel, B. and Rapoport, T.A. (1994) FEBS Letters 329, 3, 268-272  
 DIDS (4,4'-diisothiocyanatostilbene-2,2'-disulfonic acid) inhibits an early step of protein translocation across the mammalian ER membrane
86. Hartmann, E., Sommer, Th., Prehn, S., Görlich, D., Jentsch, St. and Rapoport, T.A. (1994) Nature 367, 654-657  
 Evolutionary conservation of components of the protein translocation complex
87. Kalies, K.-U., Görlich, D., and Rapoport, T.A. (1994) The Journal of Cell Biology 126, 925-934  
 Binding of ribosomes to the rough endoplasmic reticulum-mediated by the Sec61p-Complex
88. Mothes, W., Prehn, S., and Rapoport, T. A. (1994) EMBO-J. 13, No. 17, 3973-3982  
 Systematic probing of the environment of a translocating secretory protein during translocation through the ER membrane
89. Jungnickel, B., Rapoport, T.A., and Hartmann, E. (1994) FEBS Letters 346, 73-77  
 Protein translocation: common themes from bacteria to man

90. Kutay, U., Ahnert-Hilger, G., Hartmann, E., Wiedenmann, B., and Rapoport, T. A. (1994) EMBO-J. 14, No. 2, 217-223  
Transport route for synaptobrevin via a novel pathway of insertion into the ER membrane
91. Oliver, J., Jungnickel, B., Görlich, D., Rapoport, T. A., and High, Stephen (1995) FEBS Letters 362, 126-130  
The Sec61 complex is essential for the insertion of proteins into the membrane of the endoplasmic reticulum
92. Panzner, S., Dreier, L., Hartmann, E., Kostka, S., and Rapoport, T. A. (1995) Cell 81, 561-570  
Posttranslational protein transport in yeast reconstituted with a purified complex of sec proteins and Kar2p
93. Jungnickel, B., and Rapoport, T.A. (1995) Cell 82, 261-270  
A posttargeting signal sequence recognition event in the endoplasmic reticulum membrane
94. Panzner, S., Dreier, L., Hartmann, E., Kostka, S. and Rapoport, T.A. (1995) Cold Spring Harbor Symposia on Quantitative Biology, LX, 31-40  
Posttranslational protein transport into the endoplasmic reticulum
95. Lyko, F., Martoglio, B., Jungnickel, B., Rapoport, T.A., and Dobberstein, B. (1995) J. Biol. Chem. 270, 19873-19878.  
Signal sequence processing in rough microsomes.
96. Finke, K., Plath, K., Panzner, S., Prehn, S., Rapoport, T.A., Hartmann, E., and Sommer, T. (1996) EMBO-J. 15, 1482-1494  
A second trimeric complex containing homologs of the Sec61p- complex functions in protein transport across the ER membrane of S. cerevisiae
97. Rapoport, T.A., Jungnickel, B., and Kutay, U. (1996) Annu. Rev. Biochem. 65, 271-303  
Protein transport across the eukaryotic endoplasmic reticulum and bacterial inner membranes
98. Ahnert-Hilger, G., Kutay, U., Chahoud, I., Rapoport, T.A., and Wiedenmann, B. (1996) Eur. Jour. of Cell Biology 70, 1-11  
Synaptobrevin is essential for secretion but not for the development of synaptic processes
99. Whitley, P., Grahn, E., Kutay, U., Rapoport, T.A., and von Heijne, G. (1996) J. Biol. Chem. 271, 7583-7586.

A 12-residue-long polyleucine tail is sufficient to anchor synaptobrevin to the endoplasmic reticulum membrane.

100. Bacher, G., Lütcke, H., Jungnickel, B., Rapoport, T.A., and Dobberstein, B. (1996) *Nature* 381, 248-251

Regulation by the ribosome of the GTPase of the signal-recognition particle during protein targeting

101. Voigt, S., Jungnickel, B., Hartmann, E., and Rapoport, T.A. (1996) *Journal of Cell Biology* 134, 25-35

Signal sequence-dependent function of the TRAM protein during early phases of protein transport across the endoplasmic reticulum membrane

102. Rapoport, T.A., Rolls, M.M., and Jungnickel, B. (1996) *Current Opinion in Cell Biology* 8, 499-504

Approaching the mechanism of protein transport across the ER membrane

103. Hanein, D., Matlack, K.E.S., Jungnickel, B., Plath, K., Kalies, K.-U., Miller, K., Rapoport, T.A., and Akey, C. (1996) *Cell* 87, 721-732

Oligomeric rings of the Sec61p complex induced by ligands required for protein translocation

104. Wiertz, E.J.H.J., Tortorella, D., Bogoy, M., Yu, J., Mothes, W., Jones, T.R., Rapoport, T.A., and Ploegh, H.L. (1996) *Nature* 384, 432-438

Cytosolic destruction of a type I membrane protein by transfer from the ER to the proteasome involves the Sec61p complex

105. Mothes, W., Heinrich, S., Graf, R., Nilsson, I., von Heijne, G., Brunner, J., and Rapoport, T.A. (1997) *Cell* 89, 523-533.

Molecular mechanism of membrane protein integration into the endoplasmic reticulum

106. Matlack, K.E.S., Plath, K., Misselwitz, B., and Rapoport, T.A. (1997) *Science* 277, 938-941

Protein transport by purified yeast Sec complex and Kar2p without membranes

107. Neuhoef, A., Rolls, M.M., Jungnickel, B., Kalies, K.-U., and Rapoport, T.A. (1998) *Mol. Biol. Cell* 9, 103-115

Binding of signal recognition particle gives ribosome/nascent chain complexes a competitive advantage in endoplasmic reticulum membrane interaction

108. Matlack, K.E.S., Mothes, W., and Rapoport, T.A. (1998) *Cell* 92, 381-390

Protein translocation: tunnel vision



109. Hegde, R.S., Voigt, S., Rapoport, T.A., and Lingappa, V.R. (1998) *Cell* 92, 621-631
- TRAM regulates the exposure of nascent secretory proteins to the cytosol during translocation into the endoplasmic reticulum
110. Mothes, W., Jungnickel, B., Brunner, Josef, and Rapoport, T.A. (1998) *J. Cell Biol.* 142, 355-364.
- Signal sequence recognition in cotranslational translocation by protein components of the endoplasmic reticulum membrane
111. Kalies, K.-U., Rapoport, T.A., and Hartmann, E. (1998) *J. Cell Biol.* 141, 887-894.
- The  $\beta$  subunit of the Sec61 complex facilitates cotranslational protein transport and interacts with the signal peptidase during translocation
112. Plath, K., Mothes, W., Wilkinson, B.M., Stirling, C.J., and Rapoport, T.A., (1998) *Cell* 94, 795-807.
- Signal sequence recognition in posttranslational protein transport across the yeast ER membrane
113. Verhey, K., Lizotte, D.L., Abramson, T., Barenboim, L., Schnapp, B.J., and Rapoport, T.A. (1998) *J. Cell Biol.* 143, 1053-1066.
- Light chain-dependent regulation of kinesin's interaction with microtubules
114. Misselwitz, B., Staack, O., and Rapoport, T.A. (1998) *Molecular Cell* 2, 593-603.
- J proteins catalytically activate Hsp70 molecules to trap a wide range of peptide sequences
115. Meyer, T.H., Menetret, J.-F., Breitling, R., Miller, K.R., Akey, C.W., and Rapoport, T.A. (1999) *J. Mol. Biol.* 285, 1789-1800.
- The bacterial SecY/E translocation complex forms channel-like structures similar to those of the eukaryotic Sec61p complex
116. Matlack, K.E.S., Misselwitz, B., Plath, K., and Rapoport, T.A. (1999) *Cell* 97, 553-564.
- BiP acts as a molecular ratchet during posttranslational transport of prepro- $\alpha$ -factor across the ER membrane
117. Misselwitz, B., Staack, O., Matlack, K.E.S., and Rapoport, T.A. (1999) *J. Biol. Chem.* 274, 20110-20115.
- Interaction of BiP with the J-domain of the Sec63p component of the ER protein translocation complex
118. Rolls, M.M., Stein, P.A., Taylor, S.S., Ha, E., McKeon, F., and Rapoport, T.A. (1999) *J. Cell Biol.* 146, 29-43.

A visual screen of a GFP-fusion library identifies a new type of nuclear envelope membrane protein

119. Shamu, C.E., Story, C.M., Rapoport, T.A., and Ploegh, H.L. (1999) *J. Cell Biol.* 147, 45-57.

The pathway of US11-dependent degradation of MHC class I heavy chains involves a ubiquitin-conjugated intermediate

120. Rapoport, T.A., Matlack, K.E., Plath, K., Misselwitz, B. and Staack, O. (1999) *Biol. Chem.* 380, 1143-50.

Posttranslational protein translocation across the membrane of the endoplasmic reticulum

121. Schroder, K., Martoglio B., Hofmann, M., Holscher, C., Hartmann, E., Prehn, S., Rapoport, T.A. and Dobberstein, B. (1999) *EMBO J.* 18, 4804-15.

Control of glycosylation of MHC class II-associated invariant chain by translocon-associated RAMP4

122. Dreier, L. and Rapoport, T.A. (2000) *J. Cell Biol.* 148, 883-898.

In vitro formation of the endoplasmic reticulum occurs independently of microtubules by a controlled fusion reaction

123. Plath, K. and Rapoport, T.A. (2000). *J. Cell Biol.* 151, 167-178.

Spontaneous release of cytosolic proteins from posttranslational substrates before their transport into the endoplasmic reticulum

124. Prinz, W.A., Grzyb, L., Veenhuis, M., Kahana, J.A., Silver, P.A., and Rapoport, T.A. (2000) *J. Cell Biol.* 150, 461-474.

Mutants affecting the structure of the cortical endoplasmic reticulum in *S. cerevisiae*

125. Heinrich, S.U., Mothes, W., Brunner, J., and Rapoport, T.A. (2000) *Cell* 102, 233-244.

The Sec61p complex mediates the integration of a membrane protein by allowing lipid partitioning of the transmembrane domain

126. Morgan, D.G., Menetret, J.F., Radermacher, M., Neuhof, A., Akey, I.V., Rapoport, T.A. and Akey, C.W. (2000) *J. Mol. Biol.* 301, 301-321.

A comparison of the yeast and rabbit 80 S ribosome reveals the topology of the nascent chain exit tunnel, inter-subunit bridges and mammalian rRNA expansion segments

127. Prinz, A., Behrens, C., Rapoport, T.A., Hartmann, E. and Kalies, K.U. (2000) *EMBO J.* 19, 1900-6.

Evolutionarily conserved binding of ribosomes to the translocation channel via the large ribosomal RNA

FIG. 1A-D

1 CGAGGCCACGGCTTATGCAAGCAAGATCTGGAGGAGCAGTTACGGCTCTGCTCCAGTGT  
 71 AGATGAACATGACTGTACTCTACCCAGAATATTGGAAGATGTACAAGTCTCAGCTAAG  
 M T V L Y P E Y W K M Y K C Q L R  
 121 GAAAGGAGGCTGGCAACATAACAGAGAAGCAGGCCAACCTCAACTCAAGGACAGAGAGAC  
 K G G W Q H N R E Q A N L N S R T E E T  
 181 TATAAAATTTGCTGCAGCAGATTATAATACAGATCTTGAAGATTTGATAATCAGTG  
 I K F A A A H Y N T E I L K S I D N E W  
 241 CAGAAAGACTCAATGCATGCCACGGGAGCTCTGTATAGATGTGGGAAGGAGTTTGGAGT  
 R K T Q C M P R E V C I D V G K E F G V  
 301 CGCGACAAACACCTTCTTTAAACCTCCATGTGTGTCCGTCTACAGATGTGGGGGTGTCTG  
 A T N T F F K P P C V S V Y R C C G C C C  
 361 CAATAGTAGGGCGCTGCACTGCATGACACACGACGAGCTACCTCAGCAAGACGTTATT  
 N S E C L Q C M N T S T S Y L S K T L F  
 421 TGAAATTACAGTGCCTCTCTCAAGGCCCAAAACAGTAAACATCAGTTTGGCAATCA  
 E I T V P L S Q G P K P V T I S F A N H  
 481 CACTTCCTGCCGATCATGTCTAACTGGATCTTTACAGACAAGTTCATTCCATTATTAG  
 T S C R C M S K L D V Y R Q V H S I I R  
 541 ACGTTCCCTGCCAGCAACACTACCACTGTCTCAGGAGGCAACAGACCTGCCCAACCA  
 R S L P A T L P Q C Q A A N K T C P T N  
 601 TTACATGTGGAAATACATCTGCAGATGCTGGCTCAGGAAGATTTTATGTTTCTCTC  
 Y M W N N H I C R C L A Q E D F M F S S  
 661 GGATGCTGGAGATGACTCAACAGATGCAATCCATGACATCTGTGGACCAAAACAGGAGCT  
 D A G D D S T D G F H D I C C P N K E L  
 721 GGATGAAGAGACCTCTCAGTCTGTCTGCAGACCGGGCTTCGGCTGCCAGTCTGGACC  
 D E E T C Q C V C R A G L R P A S C G P  
 781 CCACAAAGAACTAGACAGAACTCATGCCAGTGTGTCTGTAACAACTCTTCCCAG  
 H K E L D R N S C Q C V C K N K L F P S  
 841 CCAATGCGGCCAAACCGAATTTGATCAAAACACATGCCAGTCTGTATGTAAGAAC  
 Q C G A N R E F D E N T C Q C V C K R T  
 901 CTGCCCCAGAAATCAACCCCTAAATCTGGAAATGTGCCTGTGAATGTACAGAAAGTCC  
 C P R N Q P L N P O K C A C E C T E S P  
 961 ACAGAAATGCTTGTAAAAAGGAAGTTCCACCACCAAAACATGCAGCTGTACAGACG  
 Q K C L L K G K K F H H Q T C S C Y R R  
 1021 GCCATGTACGAACCGCCAGAGGCTTGTGAGCCAGGATTTTCATATAGTGAAGAAGTGTG  
 P C T N R Q K A C E P G F S Y S E E V C  
 1081 TCGTGTGTCCCTTCATATTGGCAAAGACCACAAATGACTAAGATTGTACTGTTTCCA  
 R C V P S Y W Q R P O M S  
 1141 GTTCATCGATTTTCTATTATGGAAGCTGTGTGCCACAGTAGAAGTCTGTGAACAGA  
 1201 GAGACCCCTTGTGGTCCATGCTAACAAAGACAAAAGTCTGTCTTTCCTGAACCATGTGGA  
 1261 TAACCTTTACAGAAATGGACTGGAGCTCATCTGCAAAAGGCTCTGTAAAGACTGGTTTT  
 1321 CTGCCAATGACCAAAACAGCAAGATTTCTCTTGTGATTCTTTAAAGAATGACTATA  
 1381 TAATTTATTTCCACTAAAAATATTGTTTCTGCATTCAATTTTATAGCAACAACATGGT  
 1441 AAAACTCAGTGTGATCAATATTTTATATCATGCAAAATATGTTTAAATAAAATGAAAA  
 1501 TTGTATTATAAAAAAAAAAAAAA

HGS VEGF-2 350 amino acid sequence (70-419)

Minimum sequence required to maintain VEGF-C biological activity as identified by Alitalo

RCXXCC conserved motif

Alitalo VEGF-C fragments:

103-227

103-419

104-213

112-419